What question did this study set out to answer?

This study aims to evaluate the treatment utilization and residual disease burden in patients with hidradenitis suppurativa receiving adalimumab.

Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa: An Observational Cohort Study Based on Insurance Claims in the USA

View Full Paper

Ask AI

Bookmark

Authors

Observational cohort study shows high discontinuation rates in hidradenitis suppurativa patients on adalimumab, indicating treatment gaps.

This study aims to evaluate the treatment utilization and residual disease burden in patients with hidradenitis suppurativa receiving adalimumab.
Observed adult patients initiating adalimumab treatment from 2015 to 2018 and 2020 to 2021.
Used insurance claims data from Merative MarketScan® to assess treatment patterns and healthcare resource utilization.
Applied statistical methods including Kaplan–Meier estimates and multivariable proportional hazard models.
60.3% of patients discontinued adalimumab within one year; drug survival was 68.4% at 6 months and 48.0% at 12 months.
Predictors for discontinuation included female sex, younger age, and Medicaid insurance.
Despite reduced healthcare resource utilization, patients continued to require interventions such as antibiotics and surgeries.

Aleshin et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Observational cohort study shows high discontinuation rates in hidradenitis suppurativa patients on adalimumab, indicating treatment gaps.